Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
What happens to our muscles when we discontinue GLP-1s after weight loss
Instead, consistency was judged pragmatically through clinical transitivity, inspection of network geometry, comparison of random-effects and fixed-effect results, and deviance-based model fit diagnostics
The team emphasizes that despite these differences, both medications require gradual dose escalation, consistent adherence, and lifestyle changes for best results
In SURMOUNT-1, tirzepatide showed mean losses that reached about 20.9% at 72 weeks at the highest dose studied
00:18:52 Steve Small: So not super common